Nuritas Announces Formation of Scientific Advisory Board
DUBLIN, Ireland, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Nuritas, a biotechnology company discovering life-changing drugs through the power of artificial intelligence (AI) based peptide discovery, today announced the formation of its scientific advisory board (SAB) with four key appointments: Justin Siegel, Ph.D., David Chernoff, M.D., J Bruce German, Ph.D. and Luke O’Neill, Ph.D.
“We are delighted to have attracted some of the world’s leading experts in drug discovery, metabolism, immunology, food for health, proteomics and molecular diagnostics to support Nuritas as we advance our AI platform and bioactive peptide discovery to address the world’s growing healthcare needs,” said Emmet Browne, chief executive officer of Nuritas. “The formation of our SAB serves to further strengthen Nuritas’s unique approach to discover peptide-based therapies with unmatched speed and accuracy.”
Dr. Nora Khaldi, Ph.D., founder and chief scientific officer of Nuritas said, “The scientific guidance of this group of experts will be key as we accelerate and develop our unique peptide discoveries to improve human health. We are continuing to expand our scientific teams at Nuritas and the addition of the SAB further strengthens this.”
Justin Siegel, Ph.D., is an associate professor of chemistry, biochemistry and molecular medicine in the Genome Center at University of California, Davis. Dr. Siegel combines computational and experimental tools to design and discover enzymes for a wide range of applications including the treatment of human disease, the production of fuels and chemicals and the application of discovered enzymes within food systems to promote health and sustainability. As the faculty director of the Innovation Institute for Food and Health (IIFH), he has accelerated the institute’s innovation cycle and deployment of products and processes that enable safe, sustainable and secure nutrition for all. Dr. Siegel received his Ph.D. in biomolecular structure and design from the University of Washington and has a wealth of experience in translational research, having founded four companies, and currently serves as the director of business development for the Rosetta Commons.
David Chernoff, M.D., is the chief medical officer of SetPoint Medical, a clinical-stage biomedical technology company developing bioelectronic therapy for chronic inflammatory disease. He has 25 years of molecular diagnostics and biopharmaceutical experience and has served as a translational medicine consultant for more than 40 biotechnology, pharmaceutical and medical device companies, and as chief medical officer for a number of companies including Crescendo Bioscience, Adamas Pharma, Tethys Biosciences and Aquinox Pharma. He served as vice president of corporate technology at Elan Pharmaceuticals and medical director at Chiron Diagnostics where he played a pivotal role in the development of viral load assays for HIV, HCV, HBV and CMV. He was a principal with life sciences management consulting firm Keelin Reeds Ventures and entrepreneur in residence and operating partner at TPG Biotech VC Fund. Dr. Chernoff received his M.D. from New York University and completed his medical training and research in internal medicine, rheumatology and infectious disease at UCSF Medical Center.
J Bruce German, Ph.D., is food science and technology director at the Foods for Health Institute at the University of California, Davis and the co-founder of Evolve Biosystems. With the goal of improving human health through diet, Dr. German is studying the structure and function of dietary lipids, the evolution of lactation and the role of milk components in food and health. Dr. German is conducting research studies on the use of metabolic assessments to personalize diet and health, and to better understand the molecular basis for differences in human metabolism and the response to chemical composition and structural organization of foods. He received his Ph.D. from Cornell University and has published more than 400 papers on milk, lipids and food, metabolism and metabolite measurements and food functions and holds numerous patents for technologies and applications of bioactive agents.
Luke O’Neill, Ph.D., is the chair of biochemistry at Trinity College Dublin where he leads the Inflammation Research Group. Dr. O’Neill studies the molecular basis of inflammation with a focus on innate immunity, toll-like receptors, inflammasomes and metabolic reprogramming in macrophage activation and has co-founded three companies, each developing new treatments for inflammatory diseases. Dr. O’Neill was recognized by Clarivates/Thompson Reuters as one of the world’s most influential scientists, being in the top 1% in the field of immunology and has won numerous awards for his research including the European Federation of Immunology Societies medal, the International Cytokine and Interferon Society Milstein Award, The Royal Dublin Society Boyle Medal for Scientific Excellence and The Royal Irish Academy Gold Medal for Life Sciences. Dr. O’Neill received his Ph.D. in pharmacology from the University of London, carried out post-doctoral research at Cambridge U.K., and was elected a Fellow of the Royal Society in 2016.
Founded in 2014, Nuritas is solving the unmet medical needs of the world with the unparalleled capability to develop preventative and curative peptide-based treatments for disease with industry leading speed and accuracy. It is successfully doing so currently in collaboration with a number of industry leading multinationals. The company is changing the landscape of drug discovery by identifying novel peptides using a proprietary artificial intelligence (AI) platform, with in silico predictions validated by their in-house multidisciplinary team of scientists and laboratory. Nuritas engages in collaborative partnerships in the pharmaceutical and consumer goods industries to conduct peptide discovery that is faster, more accurate, and less expensive than traditional drug discovery.
Nuritas has received global recognition for the impact of its innovative technology which includes winning the overall Innovation Award at the Forbes Reinventing America Summit in 2015, the Nutrition Capital Network Venture competition in October 2016 and support from EU Horizon 2020 in 2016 for a peptide that carries the potential to prevent pre-diabetic patients from developing diabetes.
Allison Blum, Ph.D.
LifeSci Public Relations
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
WillScot Announces Closing of Warrant Exchange Offer11.12.2018 22:05 | Pressemelding
BALTIMORE, Dec. 11, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”) (NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced the closing of its previously announced exchange offer (the “Exchange Offer”) relating to certain outstanding warrants issued in 2015 (the “Warrants”). Under the terms of the Exchange Offer, each Warrant holder had the opportunity to receive 0.18182 shares of WillScot Class A Common Stock, par value $0.0001 per share (“Common Stock”), for each Warrant tendered by the holder and exchanged pursuant to the Exchange Offer. As of the closing of the Exchange Offer on December 11, 2018, 45,131,827 outstanding Warrants were properly tendered and not withdrawn in the Exchange Offer. 45,031,827 of the Warrants tendered were public warrants, representing approximately 89% of the public warrants, and approximately 100,000 Warrants tendered were private warrant
DoubleVerify and InMobi Unite to Combat Mobile App Fraud11.12.2018 18:02 | Pressemelding
Partnership brings mobile app fraud prevention to advertisers globally NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- DoubleVerify ("DV"), the leading independent provider of marketing measurement software and analytics, today announced a partnership with InMobi, a global provider of enterprise platforms for marketers. As part of the partnership, DoubleVerify will provide always-on fraud filtering and measurement for mobile in-app advertising campaigns across the InMobi Exchange globally. The integration with InMobi covers pre-bid targeting for all InMobi Exchange impressions within the leading mobile in-app platform, as well as monitoring of post-bid fraud activity, such as spoofing – enabling InMobi to continuously refine the quality of its mobile ad inventory. “DV’s partnership with InMobi demonstrates our commitment to provide consistent, comprehensive quality coverage for global brand advertisers,” said Matt McLaughlin, COO at DoubleVerify. “With ad spend increasingly concentrated in
Claroty Announces Major Enhancements to Market-Leading Industrial Cybersecurity Platform11.12.2018 15:00 | Pressemelding
Groundbreaking multispectral data acquisition and network segmentation capabilities provide deeper OT network visibility and reduce risk for industrial enterprises and critical infrastructure providers NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Claroty, the leader in operational technology (OT) network protection, today announced several significant enhancements to its award-winning Continuous Threat Detection product and technology integrations with several leading industrial automation, network infrastructure and cybersecurity providers. Already the industry’s most complete industrial control systems (ICS) cybersecurity platform, this release incorporates new functionality to provide even more “extreme” visibility into ICS networks and help industrial enterprises decrease the risk of a cyberattack. The latest release of Claroty Continuous Threat Detection provides a large number of significant enhancements including: Virtual Zones and OT Network Segmentation – an innovative approach
INN Launches Battery Metals Channel11.12.2018 15:00 | Pressemelding
The new battery metals channel is designed to educate investors with original content and expert insight on the growing battery metals industry. VANCOUVER, British Columbia, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Investing News Network (INN) announces the launch of its battery metals channel. Responding to the growth and evolution of the battery metals market, this channel will host news, educational content and expert opinions on the lithium, cobalt, graphite, vanadium and manganese market segments. “INN has been a trusted source of information on the lithium, cobalt, graphite, vanadium and manganese markets for nearly a decade, and is excited to bring these sectors together under the battery metals umbrella,” said Nick Smith, CEO and publisher at INN. “Through connections with experts, our leading team of experienced writers creates original, insightful content on battery metals. INN educates investors in the industry by providing information they may never have access to on their own,” S
Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer11.12.2018 14:30 | Pressemelding
KENSINGTON, Md. and SHORASHIM, Israel, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, announced the appointment of Hermann Russ, M.D., Ph.D., as its chief scientific officer, effective December 1, 2018. Dr. Russ invented the use of the company’s lead molecule GAL-101/MRZ-99030 for the treatment of degenerative diseases of the retina, including glaucoma and dry macular degeneration. He is also co-inventor of the so-called “trigger effect” of GAL-101/MRZ-99030 and GAL-102/MRZ 14042, which is a unique reverse prion-like self-propagation mechanism of action important for the company’s eye drop and oral treatment regimens. “We are gratified that Dr. Russ is joining the Galimedix management team, as his knowledge in the field, as well as intimate experience with the compound, have already proven instrumental in the development of our company to date,” commented Andrew Pearlman, Ph.D., CEO of Galimedix
Farmako: Cannabis distributor to become gateway to Europe11.12.2018 10:00 | Pressemelding
Company is first to apply for a licence in the United Kingdom AAA-Team pushes to become gateway to Europe Company first to apply for distribution licences in UK Support of Canadian LP to obtain EU-GMP Focus on research and development FRANKFURT, Germany, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The Frankfurt-based pharmaceutical company Farmako is a research-based pharmaceutical company that distributes medical cannabis. The company is active in all European markets that have created a legal basis for cannabinoid therapies. It is the first company for medical Cannabis pursue distribution licences in multiple European countries. Fort hat, it will rely on EU-GMP certified suppliers. The German market for medical cannabis is estimated at 19.1 million euros in 2018 and at 200 million Euros by 2019. For 2028, experts expect a market volume for medical cannabis of 7.8 billion euros in Germany, an increase by a factor of 400. The number of patients for cannabinoid therapies in Germany has grown from
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom